Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ended
Participants planned
18
Countries
1
Sites
1
Parkinson's Disease
Key facts
- Sponsor
- Arvinas Operations Inc.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Phenomena and Processes [G] - Musculoskeletal and Neural Physiological Phenomena [G11]
- Trial duration
- 28 Feb 2025 → 25 Jun 2025
- Decision date (initial)
- 2025-02-27
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Parkinson's Disease
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Arvinas Operations Inc.
- Sponsor organisation
- Arvinas Operations Inc.
- Address
- 5 Science Park
- City
- New Haven
- Postcode
- 06511-1966
- Country
- United States
Scientific contact point
- Organisation
- Arvinas Operations Inc.
- Contact name
- Clinical Trials NS
Public contact point
- Organisation
- Arvinas Operations Inc.
- Contact name
- Clinical Trials NS
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Ended | 18 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Centre for Human Drug Research
Neurology, Zernikedreef 8, 2333 CL, Leiden
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Netherlands | 2025-02-28 | 2025-06-25 | 2025-03-10 | 2025-06-25 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-01-21 | Netherlands | Acceptable 2025-02-27
|
2025-02-27 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2025-03-31 | Netherlands | Acceptable 2025-04-09
|
2025-04-09 |